• Advertise
  • Contact Us
  • Daily The Business
  • Privacy Policy
Friday, December 5, 2025
Daily The Business
  • Login
No Result
View All Result
DTB
No Result
View All Result
DTB

AstraZeneca’s Datroway extends survival in aggressive breast cancer

October 19, 2025
in World
AstraZeneca’s Datroway extends survival in aggressive breast cancer
Share on FacebookShare on TwitterWhatsapp

AstraZeneca and Daiichi Sankyo’s new breast cancer drug helped significantly extend survival in some patients in a late-stage trial, marking a potential breakthrough in one of the hardest-to-treat forms of the disease.

Patients with triple-negative breast cancer who were given the drug, Datroway, had a median overall survival of 23.7 months, compared with 18.7 months for those given just chemotherapy.

Patients on Datroway also had significantly better response to the drug and survival without progression of disease, the drug showed.

The companies presented the data at European Society for Medical Oncology Congress on Sunday.

“This is the first time we show survival superiority of a new approach like Datroway versus standard chemotherapy,” said Abder Laadem, head of late-stage clinical development oncology at Daiichi Sankyo.

Datroway belongs to a class of cancer medicines called antibody-drug conjugate, which works like guided missiles by directly delivering chemotherapy into tumor cells while limiting exposure to healthy tissue.

The drug received approval in the U.S. earlier this year for the treatment of specific types of breast and lung cancer.

The drug’s design ensures targeted delivery and reduces toxicity, Susan Galbraith, AstraZeneca’s executive vice president of oncology R&D, said.

Patients were on the therapy twice as long as chemotherapy, but still rates of Grade 3 adverse events were similar and discontinuations were lower.

Datroway’s success could position it to compete more directly with Gilead’s Trodelvy.

Ken Keller, global oncology head at Daiichi Sankyo, said he was confident Datroway would compare favourably with Trodelvy, especially due to its convenience.

“Trodelvy is every two weeks, ours is every 21 days. Those differences matter when drugs are close.”

AstraZeneca and Daiichi’s blockbuster cancer drug Enhertu is also an ADC.

“Between Enhertu and Datroway, we can actually treat 90% of all women with breast cancer.

These drugs have the chance to become the standard of care for 90% of women,“ Keller added.

Share15Tweet10Send
Previous Post

Suparco launches country’s first ‘hyperspectral satellite’

Next Post

Nvidia CEO Jensen Huang to attend APEC CEO Summit in South Korea

Related Posts

Russia’s Sberbank seeks to boost imports, labour migration from India after Putin’s visit
World

Russia’s Sberbank seeks to boost imports, labour migration from India after Putin’s visit

December 4, 2025
Tariffs, AI boom could test global growth’s resilience, OECD says
World

Tariffs, AI boom could test global growth’s resilience, OECD says

December 3, 2025
India’s Adani Group eyes $10 billion fundraise in FY27, official says
World

India’s Adani Group eyes $10 billion fundraise in FY27, official says

November 28, 2025
India expects trade deal with US by end of year, senior official says
World

India expects trade deal with US by end of year, senior official says

November 29, 2025
India approves $816mn rare earth permanent magnets manufacturing programme
World

India approves $816mn rare earth permanent magnets manufacturing programme

November 26, 2025
Niketa Patel Press Freedom at CPJ International Awards
MEDIA

Niketa Patel Highlights Press Freedom at CPJ International Awards

November 26, 2025

Popular Post

  • FRSHAR Mail

    FRSHAR Mail set to redefine secure communication, data privacy

    126 shares
    Share 50 Tweet 32
  • How to avoid buyer’s remorse when raising venture capital

    33 shares
    Share 337 Tweet 211
  • Microsoft to pay off cloud industry group to end EU antitrust complaint

    54 shares
    Share 22 Tweet 14
  • Capacity utilisation of Pakistan’s cement industry drops to lowest on record

    47 shares
    Share 19 Tweet 12
  • SingTel annual profit more than halves on $2.3bn impairment charge

    47 shares
    Share 19 Tweet 12
American Dollar Exchange Rate
  • Advertise
  • Contact Us
  • Daily The Business
  • Privacy Policy
Write us: info@dailythebusiness.com

© 2021 Daily The Business

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Add New Playlist

No Result
View All Result
  • Advertise
  • Contact Us
  • Daily The Business
  • Privacy Policy

© 2021 Daily The Business

This website uses cookies. By continuing to use this website you are giving consent to cookies being used. Visit our Privacy and Cookie Policy.